Can a patient who stopped taking Descovy (emtricitabine 200 mg + tenofovir alafenamide 25 mg) safely restart it after a break?

Can a Patient Restart Descovy After a Treatment Break?

Yes, a patient can restart Descovy after a treatment break, but the approach depends critically on whether they are using it for HIV treatment or PrEP, their viral load status, and hepatitis B status.

For HIV Treatment

Resuming Descovy (or any dolutegravir/bictegravir-based regimen) after treatment interruption is recommended even before resistance testing results return, provided adherence will be good going forward 1. This reflects the high genetic barrier to resistance of modern integrase inhibitor-based regimens.

Key Steps Before Restarting:

• Check HIV viral load immediately - If the patient was virologically suppressed before stopping, determine current status
• Test for hepatitis B - This is mandatory before restarting 2
• Assess reason for interruption - Address adherence barriers, drug interactions, or side effects that caused the break
• Order resistance testing - But don't wait for results to restart if using a high-barrier regimen 1

Evidence Supporting Restart:

Recent real-world data shows excellent outcomes when restarting bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF, similar backbone to Descovy) after treatment interruption 3:

• Among 379 patients restarting after ≥90 days off treatment, 94% of those suppressed at restart maintained suppression
• 96% of those with unknown viral status at restart achieved suppression
• 70% of those viremic at restart achieved suppression
• No integrase resistance emerged 3

Critical Hepatitis B Warning:

If the patient has hepatitis B, stopping Descovy can cause severe hepatitis flares, liver decompensation, or liver failure 2. After restarting:

• Monitor liver function closely for several months
• Consider anti-hepatitis B therapy if advanced liver disease present
• Never allow the patient to run out of medication again

For PrEP (HIV Prevention)

Before restarting Descovy for PrEP, the patient MUST be confirmed HIV-negative 2. This is non-negotiable.

Required Testing Before Restart:

• HIV antibody/antigen test - Standard 4th generation test
• If any recent exposure (<1 month) or flu-like symptoms: Use an FDA-approved test for acute HIV infection (HIV RNA or p24 antigen) 2
• Screen for other STIs - Syphilis, chlamydia, gonorrhea 2
• Hepatitis B testing 2

Symptoms Requiring Acute HIV Testing:

Look specifically for: fever, fatigue, muscle aches, headache, sore throat, vomiting, diarrhea, rash, night sweats, or swollen lymph nodes 2

Time to Protection:

The FDA label explicitly states "the time from initiation of DESCOVY for HIV-1 PrEP to maximal protection against HIV-1 infection is unknown" 2. Counsel the patient to use condoms and other prevention methods during the restart period.

Common Pitfalls to Avoid:

1. Don't restart PrEP without confirming HIV-negative status - Undetected HIV infection can lead to resistance if taking Descovy alone 2

2. Don't ignore hepatitis B status - This is the most dangerous complication of stopping/restarting 2

3. Don't assume the same regimen will work - Review what caused the interruption and address those barriers 1

4. Don't forget renal function - Descovy is not recommended if creatinine clearance is 15-30 mL/min (except for specific hemodialysis patients) 2

Monitoring After Restart:

• For HIV treatment: Viral load at 4 weeks, then every 3 months; CD4 count; liver and kidney function 1
• For PrEP: HIV testing every 3 months minimum; STI screening; adherence counseling 2

The bottom line: Restarting is generally safe and effective, but requires proper testing, addressing the cause of interruption, and close monitoring—especially for hepatitis B status.